This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nissim, I. Articles by Yudkoff, M. Search for Related Content PubMed PubMed Citation Articles by Nissim, I. Articles by Yudkoff, M.

Ifosfamide-Induced Nephrotoxicity: Mechanism and Prevention

¹ Children's Hospital of Philadelphia, Division of Child Development, Rehabilitation Medicine and Metabolic Disease and ² Division of Oncology, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Requests for reprints: Itzhak Nissim, Division of Child Development, Abramson Pediatrics Research Center, Room-510C, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104-4318. Phone: 215-590-3392; Fax: 215-590-5199; E-mail: ssitz{at}mail.med.upenn.edu.

The efficacy of ifosfamide (IFO), an antineoplastic drug, is severely limited by a high incidence of nephrotoxicity of unknown etiology. We hypothesized that inhibition of complex I (C-I) by chloroacetaldehyde (CAA), a metabolite of IFO, is the chief cause of nephrotoxicity, and that agmatine (AGM), which we found to augment mitochondrial oxidative phosphorylation and ß-oxidation, would prevent nephrotoxicity. Our model system was isolated mitochondria obtained from the kidney cortex of rats treated with IFO or IFO + AGM. Oxidative phosphorylation was determined with electron donors specific to complexes I, II, III, or IV (C-I, C-II, C-III, or C-IV, respectively). A parallel study was done with ¹³C-labeled pyruvate to assess metabolic dysfunction. Ifosfamide treatment significantly inhibited oxidative phosphorylation with only C-I substrates. Inhibition of C-I was associated with a significant elevation of [NADH], depletion of [NAD], and decreased flux through pyruvate dehydrogenase and the TCA cycle. However, administration of AGM with IFO increased [cyclic AMP (cAMP)] and prevented IFO-induced inhibition of C-I. In vitro studies with various metabolites of IFO showed that only CAA inhibited C-I, even with supplementation with 2-mercaptoethane sulfonic acid. Following IFO treatment daily for 5 days with 50 mg/kg, the level of CAA in the renal cortex was 15 µmol/L. Taken together, these observations support the hypothesis that CAA is accumulated in renal cortex and is responsible for nephrotoxicity. AGM may be protective by increasing tissue [cAMP], which phosphorylates NADH:oxidoreductase. The current findings may have an important implication for the prevention of IFO-induced nephrotoxicity and/or mitochondrial diseases secondary to defective C-I. (Cancer Res 2006; 66(15): 7824-31)

This article has been cited by other articles:

				C. Li, I. Nissim, P. Chen, C. Buettger, H. Najafi, Y. Daikhin, I. Nissim, H. W. Collins, M. Yudkoff, C. A. Stanley, et al. Elimination of KATP Channels in Mouse Islets Results in Elevated [U-13C]Glucose Metabolism, Glutaminolysis, and Pyruvate Cycling but a Decreased {gamma}-Aminobutyric Acid Shunt J. Biol. Chem., June 20, 2008; 283(25): 17238 - 17249. [Abstract] [Full Text] [PDF]

				I. Nissim, O. Horyn, I. Nissim, Y. Daikhin, S. L. Wehrli, and M. Yudkoff 3-Isobutylmethylxanthine Inhibits Hepatic Urea Synthesis: PROTECTION BY AGMATINE J. Biol. Chem., May 30, 2008; 283(22): 15063 - 15071. [Abstract] [Full Text] [PDF]